Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression

Significance More than 92% of ER− breast cancer patients die with moderate to high NOS2. In this report, we show that tumor cell NOS2, through formation of a specific flux of NO, drives ER− disease to a more aggressive phenotype. Correlation between NOS2-related genes from patient cohorts, in vitro, and animal experiments show an inflammatory loop mediated by NOS2 that makes ER− breast cancer an aggressive disease. Inflammation is widely recognized as an inducer of cancer progression. The inflammation-associated enzyme, inducible nitric oxide synthase (NOS2), has emerged as a candidate oncogene in estrogen receptor (ER)-negative breast cancer, and its increased expression is associated with disease aggressiveness and poor survival. Although these observations implicate NOS2 as an attractive therapeutic target, the mechanisms of both NOS2 induction in tumors and nitric oxide (NO)-driven cancer progression are not fully understood. To enhance our mechanistic understanding of NOS2 induction in tumors and its role in tumor biology, we used stimulants of NOS2 expression in ER− and ER+ breast cancer cells and examined downstream NO-dependent effects. Herein, we show that up-regulation of NOS2 occurs in response to hypoxia, serum withdrawal, IFN-γ, and exogenous NO, consistent with a feed-forward regulation of NO production by the tumor microenvironment in breast cancer biology. Moreover, we found that key indicators of an aggressive cancer phenotype including increased S100 calcium binding protein A8, IL-6, IL-8, and tissue inhibitor matrix metalloproteinase-1 are up-regulated by these NOS2 stimulants, whereas inhibition of NOS2 in MDA-MB-231 breast cancer cells suppressed these markers. Moreover, NO altered cellular migration and chemoresistance of MDA-MB-231 cells to Taxol. Most notably, MDA-MB-231 tumor xenographs and cell metastases from the fat pad to the brain were significantly suppressed by NOS2 inhibition in nude mice. In summary, these results link elevated NOS2 to signals from the tumor microenvironment that arise with cancer progression and show that NO production regulates chemoresistance and metastasis of breast cancer cells.

[1]  Ki-Chun Yoo,et al.  A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer. , 2013, Cancer letters.

[2]  B. Wielockx,et al.  Hypoxia‐inducible factors as key regulators of tumor inflammation , 2013, International journal of cancer.

[3]  G. Mills,et al.  Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. , 2013, Cancer research.

[4]  Yibin Kang,et al.  The metastasis-promoting roles of tumor-associated immune cells , 2013, Journal of Molecular Medicine.

[5]  D. Auboeuf,et al.  hCAF1/CNOT7 regulates interferon signalling by targeting STAT1 , 2013, The EMBO journal.

[6]  J. Bussink,et al.  Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response , 2013, Breast Cancer Research.

[7]  M. Russo,et al.  Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? , 2012, Front. Pharmacol..

[8]  S. Ambs,et al.  Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer , 2012, Breast Cancer Research.

[9]  S. Ambs,et al.  Nitric Oxide Synthase and Breast Cancer: Role of TIMP-1 in NO-mediated Akt Activation , 2012, PloS one.

[10]  S. Ambs,et al.  S-Nitrosylation of EGFR and Src Activates an Oncogenic Signaling Network in Human Basal-Like Breast Cancer , 2012, Molecular Cancer Research.

[11]  Bino John,et al.  miRNA-939 regulates human inducible nitric oxide synthase posttranscriptional gene expression in human hepatocytes , 2012, Proceedings of the National Academy of Sciences.

[12]  G. Merlino,et al.  The Two Faces of Interferon-γ in Cancer , 2011, Clinical Cancer Research.

[13]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[14]  R. Stephens,et al.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.

[15]  M. Russo,et al.  Up‐regulation of pro‐inflammatory genes as adaptation to hypoxia in MCF‐7 cells and in human mammary invasive carcinoma microenvironment , 2010, Cancer science.

[16]  K. Xie,et al.  Nitric oxide and pancreatic cancer pathogenesis, prevention, and treatment. , 2010, Current pharmaceutical design.

[17]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.

[18]  M. Russo,et al.  Induction of autophagic cell death by a novel molecule Is increased by hypoxia , 2008, Autophagy.

[19]  E. Grimm,et al.  Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. , 2008, Nitric oxide : biology and chemistry.

[20]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[21]  Bernard Roizman,et al.  Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. , 2007, Cancer research.

[22]  L. Broemeling,et al.  Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.

[23]  Ken Garber,et al.  Energy Deregulation: Licensing Tumors to Grow , 2006, Science.

[24]  S. Loibl,et al.  Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS. , 2006, Pathology, research and practice.

[25]  J. Fish,et al.  Epigenetic Basis for the Transcriptional Hyporesponsiveness of the Human Inducible Nitric Oxide Synthase Gene in Vascular Endothelial Cells1 , 2005, The Journal of Immunology.

[26]  Richard Graham Knowles,et al.  GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo , 2005, British journal of pharmacology.

[27]  J. Lagares-Garcia,et al.  Nitric Oxide Synthase as a Marker in Colorectal Carcinoma , 2001, The American surgeon.

[28]  A. Buzaid,et al.  Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  K. Kato,et al.  Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. , 2000, Cancer research.

[30]  K Raja,et al.  Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. , 2000, Cancer research.

[31]  D. Stuehr,et al.  Intracellular Assembly of Inducible NO Synthase Is Limited by Nitric Oxide-mediated Changes in Heme Insertion and Availability , 1996, The Journal of Biological Chemistry.

[32]  C. Nathan,et al.  Role of interferon regulatory factor 1 in induction of nitric oxide synthase , 1994, The Journal of experimental medicine.

[33]  S. Murphy,et al.  Nitric oxide limits transcriptional induction of nitric oxide synthase in CNS glial cells. , 1994, Biochemical and biophysical research communications.

[34]  L. Ignarro,et al.  Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. , 1993, Journal of immunology.

[35]  G. Trinchieri,et al.  Molecular Pathways Molecular Pathways : Toll-like Receptors in the Tumor Microenvironment — Poor Prognosis or New Therapeutic Opportunity , 2013 .

[36]  J. Weiss,et al.  NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression , 2013, International journal of cancer.

[37]  Jeffrey E. Lee,et al.  Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes , 2001, Annals of Surgical Oncology.